Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Quan Ren Wang"'
Autor:
Guanghui Gao, Zhe-Hai Wang, Jifeng Feng, Meijuan Huang, Xinmin Yu, Zhihua Liu, Caicun Zhou, Lihong Wu, Yina Wang, Ying Cheng, Jun Zhao, Yuan Chen, Zhiyong Ma, Weixia Li, Xiaoyan Lin, Shengxiang Ren, Kangsheng Gu, R. Guo, Jun Zhang, Quan Ren Wang, Xinfeng Yang, Gongyan Chen, Yu Yao, Jianxing He, Jianhua Chen, Jianhua Shi
Publikováno v:
Clinical Cancer Research. 27:1296-1304
Purpose: Our preclinical work suggests that appropriate angiogenesis inhibition could potentiate PD-1/PD-L1 blockade via alleviating hypoxia, increasing infiltration of CD8+ T cells and reducing recruitment of tumor-associated macrophages. We hereby
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::619eaccdde12edd8095ad0966378d4b3
https://doi.org/10.1158/1078-0432.ccr-20-3136
https://doi.org/10.1158/1078-0432.ccr-20-3136
Autor:
Enxiao Li, L Zhang, Jingfeng Liu, Guoliang Shao, Yun Zhang, Lihua Wu, Tao Yin, Guowen Yin, Zujiang Yu, Li Xu, Le-Qun Li, Zhanyu Pan, Zhenggang Ren, Jiayin Yang, Zhiming Wang, Jian-Ming Xu, Xianhai Mao, Yanqiao Zhang, Jianping Xiong, Kuansheng Ma, Quan Ren Wang, Xiaoming Chen, Xinmin Zhou, Jie Shen, Shuni Wang, Xi Chen, Shanzhi Gu, Kangsheng Gu, Jian Wu, Xiao Zhang
Publikováno v:
Clinical Cancer Research. 27:1003-1011
Purpose: We assessed the efficacy and safety of camrelizumab [an anti-programmed death (PD-1) mAb] plus apatinib (a VEGFR-2 tyrosine kinase inhibitor) in patients with advanced hepatocellular carcinoma (HCC). Patients and Methods: This nonrandomized,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bcc26009ef644042e6d563272361a73e
https://doi.org/10.1158/1078-0432.ccr-20-2571
https://doi.org/10.1158/1078-0432.ccr-20-2571
Autor:
Gairong Zhang, Yun Zhang, Yao Yue Zhang, Xin Yi, Zhiyuan Hu, Ru Jia, Jianming Xu, Jian Jun Zou, Chun Xia Chen, Chuan Hua Zhao, Chun Yan Yue, Lianpeng Chang, Quan Ren Wang, Rongrui Liu, Yan Wang
Publikováno v:
Clinical Cancer Research. 25:515-523
Purpose: This study assessed the safety and efficacy of SHR-1210 (anti-PD-1 antibody) and apatinib (VEGFR2 inhibitor) as combination therapy in patients with advanced hepatocellular carcinoma (HCC), gastric, or esophagogastric junction cancer (GC/EGJ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c4f21f3a23bba3104b59d185e70fa0e
https://doi.org/10.1158/1078-0432.ccr-18-2484
https://doi.org/10.1158/1078-0432.ccr-18-2484
Autor:
Zitao Guo, Xiaoyan Chen, Qian Chen, Dafang Zhong, Chaoying Hu, Chen Yu, Yifan Zhang, Yan Zhan, Quan-Ren Wang, Xiao-yun Liu
Publikováno v:
The Journal of Clinical Pharmacology. 58:347-356
Apatinib is a small-molecule tyrosine kinase inhibitor that has been approved for the treatment of patients with advanced-stage gastric cancer or gastroesophageal junction cancer who have progressed or recurred after at least 2 kinds of systemic chem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4173e5d8572580f26a6815bb88d93d85
https://doi.org/10.1002/jcph.1016
https://doi.org/10.1002/jcph.1016
Autor:
Yun-Ting Zhu, Zan Teng, Yi-Fan Zhang, Wei Li, Li-Xia Guo, Yun-Peng Liu, Xiu-Juan Qu, Quan-Ren Wang, Si-Yuan Mao, Xiao-Yan Chen, Da-Fang Zhong
Publikováno v:
Drug Design, Development & Therapy; May2020, Vol. 14, p1963-1970, 8p, 1 Diagram, 1 Chart, 2 Graphs